Oryzon Genomics (BME: ORY)

Currency in EUR

Last close As at 22/09/2023


0.05 (2.42%)

Market capitalisation


Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. Central nervous system (CNS) asset Vafidemstat has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder is now the lead study.

Oryzon is among the leading clinical-stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and a potentially favourable safety/efficacy profile compared with the first generation HDAC inhibitors.

Latest Insights

View More

Healthcare | Flash note

Oryzon Genomics — H123 progress and results came in as expected

Healthcare | Flash note

Oryzon Genomics — Positive safety data for vafidemstat in PORTICO

Healthcare | Flash note

Oryzon Genomics — Promising PORTICO interim results




Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Carlos Buesa


Balance Sheet

Forecast net debt (€m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual 2.7 (3.9) (9.8)
Relative (0.1) (4.8) (24.3)
52 week high/low €2.9/€2.0


Oryzon develops small molecule inhibitors for epigenetic targets. The two lead drugs are vafidemstat for CNS indications and iadademstat for oncology (both are LSD1 inhibitors, an epigenetic target). In CNS, vafidemstat is being evaluated in two Phase IIb trials, PORTICO in borderline personality disorder, which has shown encouraging interim results to date with top-line data expected in Q124, and EVOLUTION in schizophrenia. Oryzon is also hoping to register vafidemstat in its Phase I/II HOPE study targeting Kabuki syndrome by end-2023. In oncology, positive top-line data have been reported from the ALICE trial in acute myeloid leukaemia (AML) while new trials FRIDA in AML (first patient dosed in Q123) and STELLAR in SCLC could potentially be pivotal, with the FDA having now granted orphan drug designation for iadademstat in AML and SCLC. The FRIDA study represents one of Oryzon’s key strategic priorities.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 10.6 (6.9) (7.2) (8.83) N/A N/A
2022A 15.7 (5.3) (6.4) (7.26) N/A N/A
2023E 17.3 (3.7) (4.2) (3.27) N/A N/A
2024E 19.0 (9.3) (10.0) (13.64) N/A N/A

Further insights



Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest




ASCO 2023 key takeaways



Machine learning in drug development

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free